← Leaderboards
Bruce A Barron
Tulane University Of Louisiana
$403,354
Attributed
$403,354
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$403,354 · 6
By mechanism
M01$403,354 · 6
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Walter L Murfee$2,965,430
- Khalid Matrougui$5,557,211
- Kathleen S Hering-Smith$1,893,678
- Vivian A Fonseca$5,822,487
- Stryder Medoah Meadows$3,180,564
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectOpportunistic InfectionsAidsCytomegalovirusRetinitisHuman Therapy EvaluationEye Disorder ChemotherapyMedical ComplicationAntiviral AgentsCombination ChemotherapyClinical Trial Phase IGanciclovirOutcomes ResearchRelapse /RecurrenceVisual PerceptionAids TherapyAntiaids AgentCytomegalovirus RetinitisDisease /Disorder Proneness /RiskDosage FormsDrug Adverse EffectEye DisorderHerpesviridae Disease
Grant awards (10)
LONGITUDINAL STUDY OF THE OCULAR COMPLICATIONS OF AIDS$358,634
M01 · FY2006 · RR · contact PI
PHASE II/III TRIAL OF HUMAN ANTI-CMV MONOCLONAL ANTIBODY MSL 109$0
M01 · FY2001 · RR
VISTIDE TREATMENT FOR RELAPSING CMV RETINITIS IN PATIENTS WITH AIDS$0
M01 · FY2001 · RR
GANCICLOVIR-CIDOFOVIR CYTOMEGALOVIRUS (CMV) RETINITIS TRIAL--AIDS$0
M01 · FY2001 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2001 · RR
STUDIES OF THE OCULAR COMPLICATIONS OF AIDS--CMV RETINITIS RETREATMENT TRIAL$11,180
M01 · FY2000 · RR
PHASE II/III TRIAL OF HUMAN ANTI-CMV MONOCLONAL ANTIBODY MSL 109$11,180
M01 · FY2000 · RR
VISTIDE TREATMENT FOR RELAPSING CMV RETINITIS IN PATIENTS WITH AIDS$11,180
M01 · FY2000 · RR
GANCICLOVIR-CIDOFOVIR CYTOMEGALOVIRUS (CMV) RETINITIS TRIAL--AIDS$11,180
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR